Skip to main content
ZEVRA THERAPEUTICS, INC. logo

ZEVRA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · ZVRA ISIN · US4884452065 LEI · 254900CU6T74V18Y1W18 US Manufacturing
Open in API
Filings indexed 830 across all filing types
Latest filing 2019-03-22 Regulatory Filings
Country US United States of America
Listing US ZVRA

About ZEVRA THERAPEUTICS, INC.

https://zevra.com/

Zevra Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and commercializing therapies for patients with rare diseases. The company focuses on addressing significant unmet medical needs by combining a data-driven scientific approach with a patient-first perspective. Its portfolio includes commercial products such as MIPLYFFA®, an FDA-approved treatment for Niemann-Pick disease type C (NPC), and OLPRUVA®. Zevra Therapeutics also maintains a late-stage clinical pipeline, specializing in advancing promising medicines that face complex clinical and regulatory challenges for conditions with limited or no available treatments.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2019
Regulatory Filings
2019-03-22 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 95% confidence The document is titled 'SCHEDULE 14A INFORMATION' and is identified as a 'Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934.' It is marked as 'Definitive Additional Materials' related to the proxy statement for KemPharm, Inc.'s Annual Meeting of Stockholders scheduled for April 24, 2019. The content includes instructions for voting, proposals to be voted on, and board recommendations. There is no detailed financial data or management discussion, but rather materials related to soliciting shareholder votes. This matches the definition of a Proxy Solicitation & Information Statement (PSI). The document length (5770 characters) and content confirm it is the proxy materials themselves, not just an announcement of availability, so it is not an RPA. Therefore, the correct classification is PSI with high confidence.
2019-03-15 English
DEF 14A
Proxy Solicitation & Information Statement
2019-03-15 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 13, 2019, by KemPharm, Inc. It provides a Regulation FD Disclosure about a commercial update on APADAZ formulary adoption and announces a conference call and live webcast with a slide presentation. The document includes references to a press release and a presentation as exhibits. The content is an announcement of a corporate update and related investor presentation, not the full presentation or detailed financial report itself. The document length is 3612 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this filing is best classified as an Investor Presentation (IP) update announcement within a Form 8-K context, but since the actual presentation is attached as an exhibit and the document itself is a current report announcing the presentation and press release, the most appropriate classification is Regulatory Filings (RNS) as a general regulatory announcement and disclosure under Form 8-K, not the presentation itself.
2019-03-13 English
FORM S-8
Capital/Financing Update Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC. It registers additional shares of common stock under an equity incentive plan. The text includes details about the securities to be registered, registration fee calculations, incorporation by reference of prior filings, exhibits related to corporate governance documents and stock plans, and signatures of company officers. Form S-8 is specifically used for registering securities to be offered under employee benefit plans and is a type of capital raising filing. It is not an annual report, earnings release, or any other financial report. It is a capital/financing update related to equity compensation plans. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is sufficient and contains substantive content, not just an announcement or certification, so it is not RPA or RNS. Confidence is high due to clear identification of Form S-8 and its purpose.
2019-03-01 English
PROSPECTUS SUPPLEMENT
Capital/Financing Update Classification · 95% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a common stock sales agreement and registration statement. It discusses the offering of common stock, aggregate offering price, and sales agent details. This type of document is a capital raising or financing update rather than a full financial report or regulatory filing. It is not an annual report, earnings release, or management report. The content aligns with updates on company fundraising and capital structure changes, which fits the Capital/Financing Update category.
2019-03-01 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.